Thereapeutic Recommendantion for Children With a Hodgkin Lymphoma (GFAOPLH2019)

French Africa Pediatric Oncology Group

Status: Enrolling

Conditions: Staging; Therapeutic Recommendations

Treatments: Other: Observational

Study type: Observational

Funder types: Other

Identifiers

NCT05407480

GFAOP LH 2019

Details and patient eligibility

About

The GFAOP propose a simple and reproducible staging according to clinical, biological and radiological data.

Develop standardized but different therapeutic recommendations based on the availability or lack of radiation therapy in the pilot unites who will adapt these recommendations.

Full description

In high-income countries, therapeutic outcomes exceed 90% and therapeutic de-escalation is necessary to reduce mainly the effects of long-term radiotherapy. Within the same country, there are also differences between the therapeutic protocols used in the different centres.

The Experience of Sub-Saharan African Units of the Franco-African Paediatric Oncology Group (GFAOP) in the treatment of pediatric Hodgkin lymphoma in 104 patients was based on chemotherapy alone. The latter was based on COPP/ABV cures without complementary irradiation adapted to the initial stratification and modulated according to the morphological response. Overall survival at 5 years was 82% at 30 months after a median decrease of 17 months.

It seemed appropriate to bring together in a single committee the representatives of the various pilot units in order to standardize the therapeutic protocols in the African countries.

So with this recommendation the GFAOP propose a simple and reproducible staging according to clinical, biological and radiological data.

- Develop standardized but different therapeutic recommendations based on the availability or lack of radiation therapy in the pilot unit.

Enrollment: 250 estimated patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

under 18 years of age at diagnosis

• suffering from "classical" Hodgkin's disease according to the WHO classification.
• with no history of hematological malignancies or constitutional or acquired immune deficiencies

Exclusion criteria

• Over 18 years of age at diagnosis
• A history of hematological malignancies or a history of constitutional or a history of acquired immune deficiencies